This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/mesh/concept/
n27http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/pdb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/kegg-compound/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/pubchem-compound/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/iuphar/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/guide-to-pharmacology/
n23http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00120/identifier/chemspider/

Statements

Subject Item
n2:DB00120
rdf:type
n3:Drug
n3:description
An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]
n3:group
nutraceutical approved
n3:indication
L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.
owl:sameAs
n9:DB00120 n10:DB00120
dcterms:title
L-Phenylalanine
adms:identifier
n7:17295 n11:46505708 n12:L-Phenylalanine n13:3313 n14:3313 n15:5910 n16:PA450931 n17:DB00120 n18:PHE n19:6140 n20:C00079 n21:D00021
n3:mechanismOfAction
The mechanism of L-phenylalanine's putative antidepressant activity may be accounted for by its precursor role in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects. <br/>The mechanism of L-phenylalanine's possible antivitiligo activity is not well understood. It is thought that L-phenylalanine may stimulate the production of melanin in the affected skin
n3:packager
n27:271B472C-363D-11E5-9242-09173F13E4C5
n3:synonym
Phe (S)-2-Amino-3-phenylpropionic acid β-phenyl-L-alanine PHENYLALANINE beta-Phenyl-L-alanine F (S)-alpha-Amino-beta-phenylpropionic acid 3-phenyl-L-alanine L-Phenylalanine
n3:toxicity
L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia.
n3:synthesisReference
Gerald L. Bachman, "Recovery of L-phenylalanine and L-aspartic acid during preparation of .alpha.-L-aspartyl-L-phenylalanine methyl ester." U.S. Patent US4348317, issued January, 1967.
n24:hasConcept
n25:M0016544
foaf:page
n23:lph_0201.shtml
n3:IUPAC-Name
n4:271B4732-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4738-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4737-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4734-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4735-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4736-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4748-363D-11E5-9242-09173F13E4C5 n4:271B4730-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4731-363D-11E5-9242-09173F13E4C5 n4:271B472E-363D-11E5-9242-09173F13E4C5 n4:271B474A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B472F-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B474B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B473E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B473F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4739-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B473A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B473C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B473B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B473D-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed from the small intestine by a sodium dependent active transport process.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
63-91-2
n3:category
n3:containedIn
n26:271B472D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4744-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4746-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4747-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4749-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4743-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4742-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4745-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4733-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4740-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4741-363D-11E5-9242-09173F13E4C5